MA35826B1 - Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk - Google Patents

Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk

Info

Publication number
MA35826B1
MA35826B1 MA37115A MA37115A MA35826B1 MA 35826 B1 MA35826 B1 MA 35826B1 MA 37115 A MA37115 A MA 37115A MA 37115 A MA37115 A MA 37115A MA 35826 B1 MA35826 B1 MA 35826B1
Authority
MA
Morocco
Prior art keywords
compounds
ttk inhibitors
substituted
substituted triazolopyridines
triazolopyridines
Prior art date
Application number
MA37115A
Other languages
English (en)
Inventor
Gerhard Siemeister
Antje Margret Wengner
Detlef Stöckigt
Dirk Kosemund
Volker Schulze
Michael Bruening
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA35826B1 publication Critical patent/MA35826B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)

Abstract

Cette invention concerne des composés de triazolopyridine substitués de formule générale (i) : r1, r2, r3, r4, et r5 dans la formule étant tels que définis dans la description et dans les revendications ; des procédés de préparation desdits composés, des compositions pharmaceutiques et des combinaisons les contenant, l'utilisation desdits composés pour fabriquer une composition pharmaceutique destinée à traiter ou à prévenir une maladie, ainsi que des composés intermédiaires utiles dans la préparation desdits composés.
MA37115A 2011-12-12 2014-06-10 Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk MA35826B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11193011 2011-12-12
PCT/EP2012/074978 WO2013087579A1 (fr) 2011-12-12 2012-12-10 Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk

Publications (1)

Publication Number Publication Date
MA35826B1 true MA35826B1 (fr) 2014-12-01

Family

ID=47427291

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37115A MA35826B1 (fr) 2011-12-12 2014-06-10 Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk

Country Status (39)

Country Link
US (1) US9663510B2 (fr)
EP (1) EP2791136B1 (fr)
JP (1) JP6181664B2 (fr)
KR (1) KR20140105552A (fr)
CN (1) CN104114552B (fr)
AP (1) AP4017A (fr)
AR (1) AR089143A1 (fr)
AU (1) AU2012350751B2 (fr)
BR (1) BR112014014184A2 (fr)
CA (1) CA2858683A1 (fr)
CL (1) CL2014001546A1 (fr)
CO (1) CO6980657A2 (fr)
CR (1) CR20140275A (fr)
CU (1) CU20140068A7 (fr)
CY (1) CY1116958T1 (fr)
DK (1) DK2791136T3 (fr)
DO (1) DOP2014000133A (fr)
EC (1) ECSP14004812A (fr)
ES (1) ES2550677T3 (fr)
GT (1) GT201400111A (fr)
HR (1) HRP20151103T1 (fr)
HU (1) HUE025937T2 (fr)
IL (1) IL232930A (fr)
JO (1) JO3111B1 (fr)
MA (1) MA35826B1 (fr)
MX (1) MX2014007057A (fr)
PE (1) PE20141597A1 (fr)
PH (1) PH12014501319A1 (fr)
PL (1) PL2791136T3 (fr)
PT (1) PT2791136E (fr)
RS (1) RS54288B1 (fr)
RU (1) RU2632464C1 (fr)
SG (1) SG11201402820SA (fr)
SI (1) SI2791136T1 (fr)
TN (1) TN2014000254A1 (fr)
UA (1) UA112096C2 (fr)
UY (1) UY34515A (fr)
WO (1) WO2013087579A1 (fr)
ZA (1) ZA201404031B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703020A (en) * 2012-07-10 2017-08-25 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020041A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
WO2014020043A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
MA38656A1 (fr) * 2013-06-11 2018-05-31 Bayer Pharma AG Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose
PT3008062T (pt) * 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
EP2860177A3 (fr) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthèse d'arènes fonctionnalisés
KR102330668B1 (ko) * 2014-05-19 2021-11-24 유디씨 아일랜드 리미티드 고효율의 형광 유기 발광 소자
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
CN107635586B (zh) 2014-12-15 2021-09-24 拜耳医药股份有限公司 Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc)
CN105985241A (zh) * 2015-01-27 2016-10-05 邵阳学院 α-取代苯乙酸酯类化合物α-糖苷酶抑制作用及其应用
EP3310440A1 (fr) 2015-06-22 2018-04-25 Bayer Pharma Aktiengesellschaft Conjugués anticorps-médicament (adc) et conjugués lieur-promédicament (apdc) à groupes enzymatiquement clivables
WO2016207094A1 (fr) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Conjugués anticorps-principe actif (adc) d'inhibiteurs de ksp avec des anticorps anti-tweakr
WO2017060322A2 (fr) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Conjugué anticorps-médicament (adc) inhibiteur de ptefb
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑
US10968216B2 (en) 2016-10-27 2021-04-06 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
EP3558387B1 (fr) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Conjugués anticorps-principe actif (adc) spécifiques renfermant des inhibiteurs de ksp
CN106831555B (zh) * 2017-01-22 2019-09-24 中国农业大学 吡啶酰胺类化合物及其制备方法与应用
KR102668688B1 (ko) 2018-07-23 2024-05-24 삼성디스플레이 주식회사 유기 발광 소자
US12227501B2 (en) 2019-02-07 2025-02-18 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors
KR102661468B1 (ko) 2019-02-15 2024-04-30 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 전자 장치
KR102897919B1 (ko) 2019-11-14 2025-12-09 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 장치
AU2023228543A1 (en) * 2022-03-04 2024-08-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
CA2530679A1 (fr) 2003-06-30 2005-04-07 Hif Bio, Inc. Composes, compositions et procedes
WO2007065010A2 (fr) 2005-12-02 2007-06-07 Hif Bio, Inc. Composes anti-angiogenese
SG174086A1 (en) * 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
KR20100049073A (ko) 2007-07-18 2010-05-11 노파르티스 아게 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
JP2010536841A (ja) 2007-08-23 2010-12-02 アストラゼネカ アクチボラグ 増殖性疾患治療のためのｔｔｋ／ｍｐｓ１阻害剤としての２−アニリノプリン−８−オン類
JP2010536917A (ja) 2007-08-31 2010-12-02 メルク セローノ ソシエテ アノニム トリアゾロピリジン化合物と、ａｓｋ阻害剤としてのその化合物の利用法
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
SG186040A1 (en) 2007-11-27 2012-12-28 Cellzome Ltd Amino triazoles as pi3k inhibitors
WO2010092015A1 (fr) 2009-02-10 2010-08-19 Cellzome Limited Dérivés d'urée-triazolo[1,5-a]pyridine en tant qu'inhibiteurs de pi3k
KR20110116160A (ko) 2009-02-13 2011-10-25 포비어 파마수티칼스 카이네이스 저해제로서의 〔1,2,4〕트리아졸로〔1,5-ａ〕피리딘
CN102413831B (zh) 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
CA2772790C (fr) 2009-09-04 2017-06-27 Benjamin Bader Aminoquinoxalines substituees servant d'inhibiteurs de tyrosine-threonine kinases
EP2343294A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EP2343297A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Dérivés de triazolopyridine
PE20121511A1 (es) 2010-01-15 2012-12-06 Janssen Pharmaceuticals Inc Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
JP2011246389A (ja) * 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
PL2699575T3 (pl) * 2011-04-21 2015-08-31 Bayer Ip Gmbh Triazolopirydyny

Also Published As

Publication number Publication date
PL2791136T3 (pl) 2015-12-31
JP2015500308A (ja) 2015-01-05
NZ625815A (en) 2016-07-29
MX2014007057A (es) 2014-08-08
AR089143A1 (es) 2014-07-30
CA2858683A1 (fr) 2013-06-20
AP2014007731A0 (en) 2014-06-30
CR20140275A (es) 2014-08-13
AU2012350751A1 (en) 2014-06-26
PH12014501319A1 (en) 2014-09-08
PE20141597A1 (es) 2014-11-07
WO2013087579A1 (fr) 2013-06-20
TN2014000254A1 (en) 2015-09-30
CU20140068A7 (es) 2014-12-26
US9663510B2 (en) 2017-05-30
ZA201404031B (en) 2016-09-28
SI2791136T1 (sl) 2015-11-30
EP2791136B1 (fr) 2015-07-29
ES2550677T3 (es) 2015-11-11
CY1116958T1 (el) 2017-04-05
RU2632464C1 (ru) 2017-10-05
SG11201402820SA (en) 2014-06-27
JP6181664B2 (ja) 2017-08-16
ECSP14004812A (es) 2015-11-30
HRP20151103T1 (xx) 2015-11-20
DK2791136T3 (en) 2015-10-26
CO6980657A2 (es) 2014-06-27
UY34515A (es) 2013-07-31
CN104114552B (zh) 2016-12-28
BR112014014184A2 (pt) 2017-06-13
HK1203200A1 (en) 2015-10-23
IL232930A0 (en) 2014-08-03
DOP2014000133A (es) 2014-07-31
HUE025937T2 (en) 2016-05-30
CL2014001546A1 (es) 2014-10-24
GT201400111A (es) 2015-11-30
RS54288B1 (sr) 2016-02-29
IL232930A (en) 2016-07-31
AP4017A (en) 2017-01-28
CN104114552A (zh) 2014-10-22
PT2791136E (pt) 2015-11-04
US20150210683A1 (en) 2015-07-30
AU2012350751B2 (en) 2017-07-06
EP2791136A1 (fr) 2014-10-22
UA112096C2 (uk) 2016-07-25
KR20140105552A (ko) 2014-09-01
JO3111B1 (ar) 2017-09-20

Similar Documents

Publication Publication Date Title
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA34308B1 (fr) Triazolopyridines substituées
MA33768B1 (fr) Triazolopyridines
MA38227B1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA38138A1 (fr) Dérivés inédits de quinolone
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA38146A1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA38661A1 (fr) Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
MA38260B1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MA32688B1 (fr) Composes n-sulfonamido pyrazolyles polycycliques
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique